NFKB1 and lung adenocarcinoma: These results indicated that our low-dose proteasome inhibition regimen designed to block NF-κB activation of LLC lung adenocarcinoma had no effect on the growth of this tumor in solid form, but was highly effective against already established LLC-induced MPE in mice.